The FDA experiences a rapid turnover of senior leadership, including the administrative leave and departure of key executives within the Center for Biologics Evaluation and Research and Center for Drug Evaluation and Research. This period of upheaval coincides with internal disputes and changes in regulatory approach under new leadership, prompting concerns over continuity in advanced therapy regulation and impacting industry perceptions.